RxDoctor Payments Data

Elward Crawford, MD

Urology · San Diego, CANPI 1902814379

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 17.5%. Reporting peaked in 2021 at $195,289 and has fallen 73.9% since, to $50,983 in 2025. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$848,941in general payments, 2019–2025

Across 569 payments — averaging $1491.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$149K
  • Tolmar Pharmaceuticals, Inc.$146K
  • Johnson & Johnson$68K
  • Astellas Pharma US Inc$67K
  • Progenics Pharmaceuticals, Inc.$57K
  • Pfizer$50K
  • plus $312K from 34 others
$16,852in research payments, 2019–2025

Across 4 payments — averaging $4213.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$17K
  • Astellas Pharma Global Development$263

What the payments were for

  • Consulting fees$329,56139%
  • Speaking & faculty fees$430,34051%
  • Travel & lodging$74,6349%
  • Food & beverage$14,3742%
  • Education$00%
  • Entertainment$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer92$148,856
Tolmar Pharmaceuticals, Inc.47$145,607
Johnson & Johnson59$67,631
Astellas Pharma US Inc53$66,807
Progenics Pharmaceuticals, Inc.32$57,301
Pfizer43$50,265
Janssen Scientific Affairs, LLC34$43,340
Dendreon Pharmaceuticals LLC1$42,188
Myovant Sciences Inc.12$35,730
Sumitomo Pharma America, Inc.16$35,398
Tolmar, Inc.17$22,168
Ferring Pharmaceuticals LTD26$17,514
Palette Life Sciences, Inc.3$17,188
Blue Earth Diagnostics55$13,647
Ferring Sendirian Berhad9$13,573
Ferring Pharmaceuticals Inc.11$12,282
Teleflex LLC1$10,463
Clovis Oncology, Inc.8$8,920
F. Hoffmann-la Roche AG2$7,987
Merck10$6,816
Verity Pharmaceuticals Inc.2$5,434
Advanced Accelerator Applications3$4,984
Amgen4$4,524
Exelixis Inc.1$3,960
Recordati_rare_diseases_inc.1$2,800
Ferring Pharmaceuticals (asia) Co. Ltd.1$1,750
Theragenics Corporation2$350
Sanofi2$287
EDAP Technomed Inc5$215
Histosonics, Inc.2$186
Healthtronics Stone Solutions, LLC3$159
Astellas Pharma Inc1$141
Clinical Laserthermia Systems Americas Inc.1$106
Novartis2$91
AstraZeneca2$84
Urogen Pharma, Inc.1$53
Myovant Sciences GmbH1$50
Myriad Genetic Laboratories, Inc.2$46
180 Medical, Inc.1$25
ABC Home Medical Supply, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$848,941 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$19,158
Medicare patients
95
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide12$168,722
OrgovyxRelugolix23$59,760
Finasteride126$1,963
Dutasteride46$1,393
Tamsulosin Hcl96$1,311
Ciprofloxacin Hcl20$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$67,631$168,72212 claims
Sumitomo Pharma America, Inc.Orgovyx$35,398$59,76023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.

Other urology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →